Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The inducement grant includes options to purchase 90,000 shares at an exercise price of $2.63 per share under the company's 2023 Inducement Plan.
The stock option has a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (Nasdaq: TSHA), un'azienda biotecnologica in fase clinica che sviluppa terapie geniche basate su AAV per malattie del sistema nervoso centrale, ha concesso un'opzione su azioni a un nuovo dipendente. La concessione incentivante prevede opzioni per l'acquisto di 90.000 azioni a un prezzo di esercizio di 2,63 $ per azione, nell'ambito del Piano Incentivante 2023 della società.
L'opzione su azioni ha una durata di 10 anni con un piano di maturazione quadriennale: il 25% matura dopo un anno e il restante 75% matura mensilmente nei successivi 36 mesi, subordinato alla continuazione del rapporto di lavoro.
Taysha Gene Therapies (Nasdaq: TSHA), una empresa biotecnológica en fase clínica que desarrolla terapias génicas basadas en AAV para enfermedades del sistema nervioso central, ha otorgado una opción sobre acciones a un nuevo empleado. La concesión por incentivo incluye opciones para comprar 90,000 acciones a un precio de ejercicio de $2.63 por acción bajo el Plan de Incentivos 2023 de la compañía.
La opción sobre acciones tiene un plazo de 10 años con un calendario de adquisición de derechos de cuatro años: el 25% se adquiere después de un año y el 75% restante se adquiere mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo.
Taysha Gene Therapies (나스닥: TSHA)는 중추신경계 질환을 위한 AAV 기반 유전자 치료제를 개발하는 임상 단계의 바이오테크 기업으로, 신입 직원에게 주식 매수선택권을 부여했습니다. 인센티브 부여에는 회사의 2023년 인센티브 플랜에 따라 90,000주를 주당 $2.63의 행사가격으로 매수할 수 있는 옵션이 포함되어 있습니다.
이 주식 매수선택권은 10년 만기이며 4년 권리확정 일정이 적용됩니다: 1년 후 25%가 권리확정되고, 나머지 75%는 이후 36개월 동안 매월 권리확정되며, 계속 고용 상태여야 합니다.
Taysha Gene Therapies (Nasdaq : TSHA), une société biotechnologique en phase clinique développant des thérapies géniques à base d'AAV pour les maladies du système nerveux central, a accordé une option d'achat d'actions à un nouvel employé. La subvention d'incitation comprend des options d'achat de 90 000 actions à un prix d'exercice de 2,63 $ par action dans le cadre du Plan d'incitation 2023 de la société.
L'option d'achat d'actions a une durée de 10 ans avec un calendrier d'acquisition sur quatre ans : 25 % acquis après un an et les 75 % restants acquis mensuellement sur les 36 mois suivants, sous réserve de la poursuite de l'emploi.
Taysha Gene Therapies (Nasdaq: TSHA), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems entwickelt, hat einem neuen Mitarbeiter eine Aktienoption gewährt. Die Anreizzuteilung umfasst Optionen zum Kauf von 90.000 Aktien zu einem Ausübungspreis von 2,63 $ pro Aktie im Rahmen des Inducement-Plans 2023 des Unternehmens.
Die Aktienoption hat eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan: 25% wird nach einem Jahr fällig, die restlichen 75% werden über die folgenden 36 Monate monatlich vestiert, vorbehaltlich einer fortgesetzten Anstellung.
- None.
- None.
DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What stock options did Taysha Gene Therapies (TSHA) grant to its new employee?
What is the vesting schedule for TSHA's new employee stock options?
What is Taysha Gene Therapies' (TSHA) main business focus?
Under which plan were the TSHA stock options granted?
